Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AMRX save search
Amneal Reports Second Quarter 2023 Financial Results
Published: 2023-08-04 (Crawled : 11:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 10.09%
H: 18.61%
C: 14.17%
financial results
Amneal to Report Second Quarter 2023 Results on August 4, 2023
Published: 2023-07-06 (Crawled : 13:20) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -2.54%
H: 10.78%
C: 10.04%
report results
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Published: 2023-04-17 (Crawled : 13:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 11.03%
H: 10.6%
C: 9.27%
conference
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
Published: 2023-04-17 (Crawled : 11:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 11.03%
H: 10.6%
C: 9.27%
year financial results
Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
Published: 2021-02-26 (Crawled : 12:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 1.23%
H: 18.99%
C: 8.89%
financial results results
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 1.44%
H: 9.13%
C: 7.3%
disease parkinson phase 3
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
Published: 2022-07-01 (Crawled : 18:00) - prnewswire.com
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.0%
H: 6.29%
C: 5.66%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -0.52%
H: 54.73%
C: 43.21%
opana trial
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.0%
H: 0.12%
C: -0.47%
TXMD | News | $1.88 -1.05% -1.06% 29K
|
Health Technology
|
| O: 8.64%
H: 7.27%
C: 5.14%
bijuva patent therapeutics
Amneal to Report First Quarter 2022 Results on May 4, 2022
Published: 2022-04-07 (Crawled : 13:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -0.24%
H: 5.51%
C: 4.41%
report results
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
Published: 2021-02-04 (Crawled : 14:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -0.81%
H: 5.33%
C: 4.3%
results
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.96%
H: 4.27%
C: 4.27%
report year results
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-21 (Crawled : 16:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 1.13%
H: 3.83%
C: 3.55%
conference
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
Published: 2022-11-11 (Crawled : 14:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.0%
H: 4.62%
C: 3.36%
ipx203 treatment fda drug disease application parkinson’s
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.92%
H: 4.72%
C: 3.27%
migraine
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
Published: 2022-06-07 (Crawled : 13:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -3.07%
H: 2.72%
C: 2.72%
integration report esg
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
Published: 2022-04-18 (Crawled : 20:00) - prnewswire.com
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -0.73%
H: 4.4%
C: 2.69%
alymsys fda biosimilar
Amneal Receives Approval for Generic TobraDex®
Published: 2021-07-19 (Crawled : 21:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -2.09%
H: 2.37%
C: 2.37%
approval
Amneal Reports Second Quarter 2022 Financial Results
Published: 2022-08-05 (Crawled : 11:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -10.12%
H: 11.25%
C: 2.25%
results
Amneal Reports First Quarter 2023 Financial Results
Published: 2023-05-05 (Crawled : 11:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 2.17%
H: 4.79%
C: 2.13%
financial results
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: -1.31%
H: 4.08%
C: 1.99%
approval ophthalmic emulsion
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.